PSI Advisors’s AstraZeneca AZN Stock Holding History

PSI Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$2.21K	–	149
2025 Q1	$2.21K	Sell	15 -54	-78%	-$7.81K	﹤0.01%	590
2024 Q4	$8.97K	Hold	69	–	–	﹤0.01%	546
2024 Q3	$10.7K	Hold	69	–	–	﹤0.01%	525
2024 Q2	$10.6K	Buy	69 +18	+35%	+$2.71K	﹤0.01%	503
2024 Q1	$6.93K	Hold	51	–	–	﹤0.01%	540
2023 Q4	$6.79K	Hold	51	–	–	﹤0.01%	566
2023 Q3	$6.83K	Buy	51 +1	+2%	+$137	﹤0.01%	546
2023 Q2	$7.17K	Hold	50	–	–	﹤0.01%	536
2023 Q1	$6.95K	Hold	50	–	–	﹤0.01%	493
2022 Q4	$6.7K	Sell	50 -175	-78%	-$21.9K	﹤0.01%	480
2022 Q3	$25K	Buy	225 +1	+0.4%	+$127	0.01%	298
2022 Q2	$30K	Hold	224	–	–	0.01%	300
2022 Q1	$30K	Hold	224	–	–	0.01%	313
2021 Q4	$26K	Sell	224 -200	-47%	-$23.5K	0.01%	357
2021 Q3	$51K	Buy	+424	New	+$49.4K	0.02%	288
2020 Q1	–	Sell	-937	Closed	-$93K	–	147
2019 Q4	$93K	Buy	+937	New	+$88.2K	0.06%	195

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PSI Advisors's AZN Position: Q2 2025 in Review

PSI Advisors sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 15 shares — an estimated $2.21K sold.

PSI Advisors first reported a position in AZN in Q4 2019 and held it in 16 quarters. The position peaked at $93K in Q4 2019. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

PSI Advisors reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
PSI Advisors sold 15 AstraZeneca shares in Q2 2025, an estimated $2.21K.
PSI Advisors first reported a position in AstraZeneca in Q4 2019 and held it in 16 quarters.
PSI Advisors's AstraZeneca position peaked at $93K in Q4 2019.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.